Press release
Inflammatory Bowel Disease (IBD) Clinical Market Expands as Biologics, JAK Inhibitors & Precision Gastroenterology Drive Next-Generation Care
Inflammatory Bowel Disease (IBD) Clinical Market
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/73633
Market Overview
The Global Inflammatory Bowel Disease Clinical Market is projected to grow at a strong CAGR of 7.2% from 2023 to 2030, driven by:
• Rising incidence of ulcerative colitis and Crohn's disease
• Strong adoption of biologics (anti-TNF, anti-IL-23, anti-integrin)
• Expansion of JAK inhibitors & S1P receptor modulators
• Advances in diagnostic imaging, endoscopy, and biomarker-based monitoring
• Greater awareness and early detection initiatives
IBD represents a long-term therapeutic challenge, requiring ongoing medication, monitoring, dietary management, and sometimes surgical intervention.
Key Takeaways
• Biologics and targeted small molecules are reshaping IBD treatment algorithms.
• Non-invasive diagnostics-stool biomarkers, capsule endoscopy, and AI-assisted imaging-are increasing early diagnosis accuracy.
• Personalized therapy, including therapeutic drug monitoring (TDM), is improving remission rates.
• Rising prevalence in Asia and emerging economies is expanding global clinical demand.
Market Story - Why IBD Clinical Management Is Evolving Rapidly
IBD is a chronic relapsing-remitting disease with no complete cure, requiring lifelong management. Its rising incidence is linked to:
• Diet & lifestyle changes
• Genetic predisposition
• Urbanization
• Increased immune dysregulation
• Gut microbiome alterations
Modern IBD care emphasizes:
• Early aggressive therapy for high-risk patients
• Biologics with improved response durability
• Oral small molecules (JAK, S1P modulators) offering convenience
• Advanced imaging & endoscopy for disease monitoring
• Personalized treatment strategies guided by biomarkers
The shift toward precision gastroenterology is delivering better remission rates, fewer hospitalizations, and improved quality of life.
Market Segmentation
By Disease Type
• Ulcerative Colitis (UC)
• Crohn's Disease (CD)
By Diagnosis Method
• Colonoscopy
• Endoscopy (Flexible Sigmoidoscopy)
• CT & MRI Enterography
• Capsule Endoscopy
• Stool Biomarkers (Calprotectin, Lactoferrin)
• Blood Tests & Genetic Markers
By Treatment Type
Conventional Therapies
• Aminosalicylates (5-ASA)
• Corticosteroids
• Immunomodulators (Azathioprine, 6-MP)
Biologics
• Anti-TNF Agents
• Anti-Integrin Therapies
• Anti-IL-12/23 and Anti-IL-23 Inhibitors
Targeted Small Molecules
• JAK Inhibitors
• S1P Receptor Modulators
Other Therapies
• Antibiotics
• Nutritional & Microbiome Therapies
• Surgical Interventions
By End User
• Hospitals
• Gastroenterology Clinics
• Diagnostic Centers
• Research Institutes
• Specialty IBD Centers
• Telemedicine Platforms & Home-Care Settings
By Region
• North America - Strong biologics adoption and specialized IBD centers
• Europe - High awareness and access to advanced therapies
• Asia Pacific - Fastest-growing due to increasing incidence and healthcare modernization
• Latin America - Rising diagnostics and access to biologics
• Middle East & Africa - Improving gastroenterology infrastructure
Explore Full Report here: https://exactitudeconsultancy.com/reports/73633/inflammatory-bowel-disease-clinical-market
Recent Developments
• Launch of next-generation IL-23 inhibitor biologics with superior remission rates.
• Development of JAK inhibitors and S1P modulators offering oral alternatives to biologics.
• AI-driven endoscopy systems for improved mucosal healing assessment.
• Research into microbiome-based therapeutics and fecal microbiota transplantation (FMT).
• Digital gastrointestinal monitoring tools enabling remote patient tracking.
Expert Quote - Irfan Tamboli (Required)
"IBD care is being transformed by precision medicine, advanced biologics, and digital diagnostic technologies. With rising global incidence, the need for personalized and long-term management approaches has never been more critical."
- Irfan Tamboli, Business Development Executive, Exactitude Consultancy
Key Market Drivers
• Increasing global prevalence of UC & Crohn's disease
• High adoption of biologics and targeted therapies
• Advances in endoscopic imaging and remote monitoring
• Strong R&D investment in immune-modulating drugs
• Expanding diagnostic access in emerging economies
Market Forecast & Outlook
Through 2030, the IBD clinical market will experience significant growth as:
• Biologics pipelines expand with IL-23-only therapies
• Oral small molecules become mainstream maintenance therapies
• Digital GI tools improve patient monitoring
• Personalized therapy and TDM become routine practice
Asia Pacific is expected to be the fastest-growing region, driven by urbanization, lifestyle shifts, and improved healthcare access.
Government & Regulatory Support
• Approval of new biologics and targeted therapies
• National programs raising awareness of gut health
• Health insurance policies supporting biologic reimbursement
• Research grants for gastrointestinal disease innovation
Conclusion
The inflammatory bowel disease clinical market is undergoing a major evolution fueled by biologic innovation, targeted therapies, and digital diagnostic advancements. As global prevalence rises, the market is poised for strong, sustained growth driven by precision treatment strategies and improved access to modern gastroenterology care.
This report is also available in the following languages : Japanese (炎症性腸疾患の臨床市場), Korean (염증성 장 질환 임상 시장), Chinese (炎症性肠病临床市场), French (Marché clinique des maladies inflammatoires de l'intestin), German (Klinischer Markt für entzündliche Darmerkrankungen), and Italian (Mercato clinico delle malattie infiammatorie intestinali), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/73633
Related Reports
Multiomics Market
https://exactitudeconsultancy.com/reports/73501/multiomics-market
Single-Cell Omics Market
https://exactitudeconsultancy.com/reports/73503/single-cell-omics-market
Sustainable Laboratory Plasticware Market
https://exactitudeconsultancy.com/reports/73505/sustainable-laboratory-plasticware-market
Medical Waste Management Market
https://exactitudeconsultancy.com/reports/73507/medical-waste-management-market
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Inflammatory Bowel Disease (IBD) Clinical Market Expands as Biologics, JAK Inhibitors & Precision Gastroenterology Drive Next-Generation Care here
News-ID: 4293500 • Views: …
More Releases from Exactitude Consultancy
Rhabdomyosarcoma (RMS) Clinical Market Strengthens as Pediatric Oncology Advance …
Rhabdomyosarcoma (RMS)-a rare but aggressive pediatric soft-tissue cancer-is gaining renewed clinical attention as researchers push for better diagnostics, innovative treatment combinations, and targeted therapies. Advancements in precision oncology, supportive care, and early diagnosis are reshaping the global RMS clinical landscape. This press release highlights key market trends, epidemiological insights, therapeutic developments, segmentation analysis, and the evolving strategies improving outcomes for children and adolescents with RMS.
Download Full PDF Sample Copy of…
Plaque Psoriasis (Psoriasis Vulgaris) Clinical Market Strengthens as Biologics, …
Plaque psoriasis-one of the most common chronic inflammatory skin diseases-affects millions globally and requires long-term, individualized clinical management. As biologics, targeted small molecules, and digital dermatology tools advance rapidly, the plaque psoriasis clinical market is entering a new era of therapeutic innovation. This press release highlights key trends, diagnostic advancements, market drivers, and segment insights driving the evolution of psoriasis care worldwide.
Download Full PDF Sample Copy of Market Report @https://exactitudeconsultancy.com/request-sample/73631
Market…
Bronchitis Clinical Market Grows as Respiratory Infections, Air Pollution, and C …
The global bronchitis clinical market is witnessing steady expansion as respiratory infections, air pollution exposure, smoking prevalence, and chronic pulmonary conditions continue to rise worldwide. Healthcare systems are increasingly adopting advanced diagnostics, targeted therapeutics, and integrated respiratory care models. This press release highlights key market trends, epidemiological drivers, segment insights, and the technological innovation shaping modern bronchitis care.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/73629
Market Overview
The Global Bronchitis…
Bio-Pharmaceutical Outsourcing Market Surges as Biologics, Cell & Gene Therapy, …
The global biopharmaceutical industry is rapidly shifting toward outsourced services as pipelines become more complex, timelines compress, and demand for specialized expertise intensifies. From biologics and biosimilars to cell and gene therapies, outsourcing partners-including CROs, CDMOs, and specialized service providers-are becoming indispensable. This press release highlights the major trends, market expansion factors, segmentation insights, and recent developments redefining the biopharmaceutical outsourcing landscape.
Download Full PDF Sample Copy of Market Report @…
More Releases for IBD
Ace Therapeutics Unveils Imaging Services for Precise Characterization of IBD An …
Ace Therapeutics launched its translational imaging services specifically designed to accurately characterize Inflammatory Bowel Disease (IBD) animal models.
New York, USA - May 28, 2025 - Ace Therapeutics, a leader in preclinical research solutions, launched its translational imaging solutions specifically designed to accurately characterize Inflammatory Bowel Disease (IBD) animal models. This breakthrough offering empowers researchers with high-resolution, quantitative data to enhance drug development and mechanistic studies.
Image: https://www.getnews.info/uploads/3c0755ac659fa5075e809ffd1b893496.jpg
Imaging techniques play a crucial…
Inflammatory Bowel Disease (IBD) Market Size, Growth Insights, and Future Trends
Inflammatory Bowel Disease (IBD) continues to pose significant challenges for individuals and healthcare systems worldwide. With its increasing prevalence, the demand for effective treatments is driving market growth. The IBD treatment market is projected to grow from USD 19.91 billion in 2023 to USD 33.19 billion by 2032, reflecting a compound annual growth rate (CAGR) of 5.5% during the forecast period.
Download Statistical Data: https://www.towardshealthcare.com/download-statistics/5149
Key Market Highlights
• Crohn's Disease Dominates: Crohn's disease…
Canada Inflammatory Bowel Disease (IBD) Market Size & Growth Analysis Report, 20 …
The Canada IBD market is estimated to grow significantly at a CAGR of around 5.2% during the forecast period. Rising prevalence and incidence of IBD across the country is the major driving factor for the market. Canada has among the highest reported prevalence and incidence rates of IBD across the globe. As per CCC, in 2018, nearly 270,000 Canadians were living with IBD, of which 135,000 individuals with Crohn’s disease,…
Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031
Visiongain has published a new report on Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031: Forecasts by Drug Class (Biologics, Aminosalicylates, Corticosteroids, Antibiotics, Immunomodulators, Others), by Indication (Crohn’s Disease, Ulcerative Colitis), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) AND Regional and Leading National Market Analysis PLUS Analysis of Leading IBD Drug Companies AND COVID-19 Recovery Scenarios.
Global Inflammatory Bowel Disease (IBD) drugs market was valued at US$ US$xx…
US Inflammatory Bowel Disease (IBD) Therapeutics Market Research and Forecast 20 …
The US IBD therapeutics market is estimated to grow significantly at a CAGR of around 4.7% during the forecast period. The factors such as the significant prevalence of IBD such as Crohn’s disease and ulcerative colitis across the country contributing to the market growth. As per the Centers for Disease Control and Prevention (CDC), the prevalence of Crohn’s disease and ulcerative colitis in the US was 201 and 238 per…
Global Inflammatory Bowel Disease (IBD) Therapeutics Market, Share, Trends & For …
The global IBD therapeutics market is estimated to grow significantly at a CAGR of around 5.0% during the forecast period. The rise in the number of IBD such as Crohn's disease and ulcerative colitis is augmenting the growth of the global IBD therapeutics market. The increasing prevalence of IBD results in the need for research for the treatment of IBD and innovations in healthcare systems to manage this complex and…
